Current Clinical Trials

Department: Family Practice
Diagnosis: Infectious Disease
Principal Investigator:
Sub-Investigator(s):
Sponsor: Pfizer
Indentifier #: NCT00665561
Title: An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Srivatana M.D., Ukorn
Sponsor: Cubist
Indentifier #: NCT01598311
Title: LCD-CDAD-11-06 entitled, "A RANDOMIZED, DOUBLE-BLINDED, ACTIVE-CONTROLLED STUDY OF CB-183,315 IN PATIENTS WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA" CUBIST
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson M.D., Michael
Sponsor: Salix
Indentifier #: NCT02240121
Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects with Active Moderate Crohn's Disease (RECD3125)
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT00843882
Title: E2905, Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01810913
Title: RTOG 1216, Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT01169337
Title: E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC